Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis.
Tanaka, Yoshiya
Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. [electronic resource] - Modern rheumatology Jan 2018 - 58-65 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
1439-7609
10.1080/14397595.2017.1337056 doi
Adult
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized--adverse effects
Antirheumatic Agents--adverse effects
Arthritis, Rheumatoid--drug therapy
Chemokine CX3CL1--immunology
Female
Humans
Male
Middle Aged
Safety, pharmacokinetics, and efficacy of E6011, an antifractalkine monoclonal antibody, in a first-in-patient phase 1/2 study on rheumatoid arthritis. [electronic resource] - Modern rheumatology Jan 2018 - 58-65 p. digital
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
1439-7609
10.1080/14397595.2017.1337056 doi
Adult
Antibodies, Monoclonal--adverse effects
Antibodies, Monoclonal, Humanized--adverse effects
Antirheumatic Agents--adverse effects
Arthritis, Rheumatoid--drug therapy
Chemokine CX3CL1--immunology
Female
Humans
Male
Middle Aged